Free Webinar Explores Safe Scaling of Pressure Reactions
News May 24, 2013
Mettler Toledo has presented the next installment in its thought-leading, on-demand webinar series. Entitled “Characterize, Optimize and Scale-up Pressure Reactions - Challenges and Solutions” and presented by Mettler Toledo Market Manager Brian Wittkamp, PhD, the free presentation reviews critical pressure-reaction design parameters.
It also explores enabling technologies such as Fourier Transform Infrared technology (FTIR) that help chemists gain better reaction control and more valuable reaction information for easier, safer and more cost-effective scale-up.
Although the objectives of chemical development have not changed in recent years, Dr. Wittkamp notes that the market has.
Chemists must bring new products to market faster, necessitating quick identification of workable opportunities and even quicker rejection of untenable ones.
FTIR instruments (ReactIR) helps deliver a process that is safe, economically viable and robust by providing critical understanding at small scale where lab resources, including development time, can be limited.
The data collected then allows these findings to be applied at larger scales.
Using a Mettler Toledo Easy Max synthesis workstation combined with Mettler Toledo ReactIR technology, two pressurized hydrogenation reactions are analyzed.
In the first, a one-step hydrogenation of a substitute 2-cyclohexene-1-one, mix rates are shown to influence reaction times. In the second, a complex hydrogenation of substituted hydrobenzene, accumulation of unstable hydroxylamine intermediate is prevented.
In each case, in situ FTIR data provides higher-value reaction chemistry information when compared with potentially time-consuming and error-prone offline sampling techniques.
Precise FTIR monitoring of critical parameters is shown to enhance researchers’ understanding and enable faster, safer optimization.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE